Kyverna Therapeutics

Karen Walker, Chief Technology Offiicer 

Oct. 11 | 11:15am | Oxford Biomedica Ballroom 

Emeryville, CA 


In-person Presentation 

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. We combine advanced T cell engineering and synthetic biology to target the underpinnings of autoimmunity: chimeric antigen receptor T cells (CAR T) with properties uniquely suited for use in autoimmunity, and synReg T cells (synthetic regulatory T cells) to suppress pathogenic immune cells in specific tissues. Our lead program, KYV-101, is a novel clinical-stage anti-CD19 chimeric antigen receptor (CAR) T cell construct with properties uniquely suited for use in autoimmune diseases. It is designed to improve clinical tolerability, through a fully human anti-CD19 CAR with rationally assembled costimulatory domains. In a 20-patient Phase I/II study in oncology, expected anti-lymphoma activity was associated with a significant reduction of cytokines released. KYV-101 will enter clinical development in 2022. Additionally, Kyverna is developing an allogeneic version (KYV-201), using Intellia’s proprietary ex vivo CRISPR/Cas9-based allogeneic platform. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions